The next logical step is to validate the safety and effectiveness of selected GHRH-R peptides in clinical trials, possibly including patients with lung injury, sarcoid, bronchogenic carcinoma, or viral pneumonia such as that due to SARS-CoV-2. The gene discussed is GHRHR; the disease is viral pneumonia.